Current status of dendritic cell immunotherapy of malignancies

International Reviews of Immunology

Volumn 22, Issue 3-4, 2003, Pages 255-281

  Mosca, Paul J ^a   Clay, Timothy M ^a   Lyerly, H Kim ^a   Morse, Michael A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Box 3233 ^*  (United States)

Author keywords

Active immunotherapy; Dendritic cells; Tumor antigens

Indexed keywords

CANCER VACCINE;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL MATURATION; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; MELANOMA; MYELOMA; PROSTATE CARCINOMA; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

CLINICAL TRIALS; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0037599398     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180305223     Document Type: Review

References (124)

1. C. Esche, M.R. Shurin, and M.T. Lotze, The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther., 1: 72-81, 1999.
2. K. Tarte and B. Klein, Dendritic cell-based vaccine: A promising approach for cancer immunotherapy. Leukemia, 13: 653-663, 1999.
3. M.A. Morse and H.K. Lyerly, Clinical applications of dendritic cell vaccines. Curr. Opin. Mol. Ther., 2: 20-28, 2000.
4. L. Wu, S. Vandenabeele and K. Georgopoulos, Derivation of dendritic cells from myeloid and lymphoid precursors. Int. Rev. Immunol., 20: 117-135, 2001.
5. L. Galibert, C.R. Maliszewski, and S. Vandenabeele, Plasmacytoid monocytes/T cells: A dendritic cell lineage? Semin. Immunol., 13: 283-289, 2001.
6. Y.J. Liu, H. Kanzler, V. Soumelis, and M. Gilliet, Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol., 2: 585-589, 2001.
7. M. Moser and K.M. Murphy, Dendritic cell regulation of TH1-TH2 development. Nat. Immunol., 1: 199-205, 2000.
8. A. Lanzavecchia and F. Sallusto, The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics. Curr. Opin. Immunol., 13: 291-298, 2001.
9. D.B. Fearnley, L.F. Whyte, S.A. Carnoutsos, A.H. Cook, and D.N. Hart, Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood, 93: 728-736, 1999.
10. V.L. Reichardt, C.Y. Okada, A. Liso, C.J. Benike, K.E. Stockerl-Goldstein, E.G. Engleman, K.G. Blume, and R. Levy, Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood, 93: 2411-2419, 1999.
11. F.J. Hsu, C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy, Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
12. E.J. Small, P. Fratesi, D.M. Reese, G. Strang, R. Laus, M.V. Peshwa, and F.H. Valone, Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol., 18: 3894-3903, 2000.
13. M.Q. Lacy, P. Wettstein, A. Dispenzieri, D.A. Gastineau, P.R. Greipp, R. Fonseca, J. Lust, T. Witzig, S.V. Rajkumar, F. Valone, R.A. Kyle, and M.A. Gertz, Dendritic cell based idiotype vaccination for primary systemic amyloidosis (abst 704). Blood, 96: 164a, 2000.
14. M.Q. Lacy, P. Wettstein, M.A. Gertz, D.A. Gastineau, P.R. Greipp, R. Fonseca, A. Dispenzieri, J. Lust, T. Witzig, S.V. Rajkumar, F. Valone, and R.A. Kyle, Dendritic cell-based idiotype vaccination in post transplant multiple myeloma (abst 1613). Blood, 96: 374a, 2000.
15. J. Meuller-Berghaus, T.K. Hoffmann, J.T. Johnson, T.L. Whiteside, and W.J. Storkus, Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck (abst 122). Proc. Am. Assoc. Cancer Res., 42: 23, 2000.
16. O. Eremin, S. Sutthaporn, B. Al-Sarireh, M.A. Elsheemy, W. Vassanasiri, and A. Robins, Defective dendritic cell function and dysregulation of cytokine cascade in women with breast cancer: factors inducing tumor growth (abst 125). Proc. Am. Assoc. Cancer Res., 42: 23, 2001.
17. D.I. Gabrilovich, J. Corak, I.F. Ciernik, D. Kavanaugh, and D.P. Carbone, Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-90, 1997.
18. R.D. Brown, B. Pope, J. Gibson, A. Murray, D. Sze, D. Hart, and D. Joshua, Dendritic cells from patients with myeloma are numerically normal but functionally defective due to TGFb1 and IL-10 inhibition of the upregulation of CD80 expression after huCD40LT stimulation (abst 695). Blood., 96: 161a, 2000.
19. N. Romani, S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P.O. Fritsch, R.M. Steinman, and G. Schuler, Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
20. H. Cao, V. Verge, C. Baron, C. Martinache, A. Leon, S. Scholl, N.C. Gorin, Salamero, J., Assari, S., Bernard, J., and M. Lopez, In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J. Hematother. Stem Cell Res., 9: 183-194, 2000.
21. K. Sato, H. Nagayama, K. Tadokoro, T. Juji, and T.A. Takahashi, Interleukin-13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells. Exp. Hematol., 27: 326-336, 1999.
22. M.A. Morse, H.K. Lyerly, and Y. Li, The role of IL-13 in the generation of dendritic cells in vitro. J. Immunother., 22: 506-513, 1999.
23. K. Tarte, G. Fiol, and B. Klein, Extensive characterization of dendritic cells generated in serum-free conditions: Regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia, 14: 2182-2192, 2000.
24. D.I. Gabrilovich, S. Nadaf, J. Corak, J.A. Berzofsky, and D.P. Carbone, Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol., 170: 111-119, 1996.
25. A. de Baey, I. Mende, G. Riethmueller, and P.A. Baeuerle, Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur. J. Immunol., 31: 1646-1655, 2001.
26. A. Hinkel, C.L. Tso, B.J. Gitlitz, N. Neagos, I. Schmid, S.H. Paik, J. deKernion, R. Figlin, and A. Belldegrun, Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J. Immunother., 23: 83-93, 2000.
27. + progenitor cells. J. Biol. Regul. Homeost. Agents., 15: 49-52, 2001.
28. B. Chen, P. Stiff, G. Sloan, J. Kash, R. Manjunath, M. Pathasarathy, D. Oldenburg, K.E. Foreman, and B.J. Nickoloff, Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin. Immunol., 98: 280-292, 2001.
29. S. Titzer, O. Christensen, O. Manzke, H. Tesch, J. Wolf, B. Emmerich, C. Carsten, V. Diehl, and H. Bohlen, Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br. J. Haematol., 108: 805-816, 2000.
30. A. Mackensen, B. Herbst, J.L. Chen, G. Kohler, C. Noppen, W. Herr, M. Bermont, M. Goldman, and T. Velu, Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukoc. Biol., 69: 937-943, 2001.
31. H. Bernhard, M. Lohmann, W.Y. Batten, J. Metzger, H.F. Lohr, C. Peschel, K.M. zum Buschenfelde, and S. Rose-John, The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp. Hematol., 28: 365-372, 2000.
32. + progenitors and from monocytes are not functionally equivalent anti gen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res., 57: 5534-5541, 1997.
33. + T cells. J. Immunol., 163: 3597-3604, 1999.
34. + progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J. Immunother., 23: 48-58, 2000.
35. R.M. Syme, P. Duggan, T. Bryan, D. Stewart, and S. Gluck, Dendritic cells can prime potent CTL responses to CML (abst 116). Proc. Am. Assoc. Cancer Res., 42: 22, 2001.
36. D.F. Claxton, J. McMannis, M. Delima, R. Champlin, and A. Choudhury, Generation and clinical use of leukemia derived dendritic cell activated lymphocytes in patients with chronic myelogenous leukemia (abst 621). Blood, 96: 145a, 2000.
37. W.M. Smit, M. Rijnbeek, C.A. van Bergen, R.A. de Paus, H.A. Vervenne, M. van de Keur, R. Willemze, and J.H. Falkenburg, Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum. Immunol., 53: 216-223, 1997.
38. + autologous dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transplant., 26(Suppl) 2: S46-S49, 2000.
39. J. Westermann, J. Kopp, I. Korner, C. Dohner, H. Dohner, J. Mohm, G. Ehninger, G. Richter, B. Dorken, and A. Pezzutto, Dendritic cells for vaccination in bcr/abl-positive chronic myelogenous leukemia (abst 619). Blood, 96: 144a, 2001.
40. A. Cignetti, E. Bryant, B. Allione, A. Vitale, R. Foa, and M.A. Cheever, CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood, 94: 2048-2055, 1999.
41. M. Narita, M. Takahashi, A. Liu, K. Nikkuni, T. Furukawa, K. Toba, S. Koyama, K. Takai, M. Sanada, and Y. Aizawa, Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp. Hematol., 29: 709-719, 2001.
42. R. Rouas, P. Lewalle, A. Soree, and P. Martiat, Mixed autologous leukocytes reactions performed using matured CML dendritic cells and CD8 or CD4 T-cells results in colony inhibition only with CD4 cultured with IL-12 throughout and is not leukemia specific (abst 620). Blood, 96: 145a, 2000.
43. H. Yasukawa, H. Ohminami, T. Takahashi, H. Hirai, and S. Fujita, HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogeneous leukemia-derived dendritic cells to CD4+ lymphocytes (abst 616). Blood, 96: 144a, 2000.
44. A. Mackensen, R. Drager, M. Schlesier, R. Mertelsmann, and A. Lindemann, Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol. Immunother., 49: 152-156, 2000.
45. P. Kalinski, P.L. Vieira, Q. Cai, R. Mailliard, M. Lotze, and M.L. Kapsenberg, Polarization of DC functions: Implications for anti-cancer vaccine design (abst 973). Proc. Am. Soc. Cancer Res., 42: 181, 2001.
46. Y. Suen, S. Lee, M. Loudovaris, and J. Bender, Function of dendritic cells generated from monocytes enriched by CD2/CD19 antibody depletion and matured with different agents (abst 136). Proc. Am. Assoc. Cancer Res., 42: 25, 2001.
47. S. Lee, E. Wong, F. Aono, K. Hines, J. Lee, T. Trischmann, Q. Chau, W.C. Kopp, C. Carter, J. Bender, and E.J. Read, Ex vivo generation of dendritic cells from enriched monocytes by elutriation vs. immunomagnetic depletion of T and B cells (abst 138). Proc. Am. Assoc. Cancer Res., 42: 26, 2001.
48. M.-T. Duffour, N. Bercovici, A. Boyer, C. Boccaccio, A. Nardin, I. Chauvet, M. Salcedo, S. Agrawal, F. Heshmati, and J.-P. Abastado, Clinical grade dendritic cells generated with GM-CSF and IL-13 are potent inducers of tumor antigen-specific T cell responses and highly susceptible to adenovirus infection without alteration of their phenotype (abst 972). Proc. Am. Assoc. Cancer Res., 42: 181, 2001.
49. + cells in cancer patients. Cancer Res., 60: 1934-1941, 2000.
50. S.M. Kiertscher, B.J. Gitlitz, R.A. Figlin, and M.D. Roth, Treatment with GM-CSF and IL-4 preferentially activates circulating dendritic cells in cancer patients. (abst 1479). Proc. Am. Assoc. Cancer Res., 42: 275, 2001.
51. J.E. Janik, L.L. Miller, W.C. Kopp, D.D. Taub, H. Dawson, D. Stevens, P. Kostboth, B.D. Curti, K.C. Conlon, B.K. Dunn, S.E. Donegan, R. Ullrich, W.G. Alvord, B.L. Gause, and D.L. Longo, Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients. Clin. Immunol., 93: 209-221, 1999.
52. E. Maraskovsky, K. Brasel, M. Teepe, E.R. Roux, S.D. Lyman, K. Shortman, and H.J. McKenna, Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med., 184: 1953-1962, 1996.
53. H.J. McKenna, Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol., 8: 149-154, 2001.
54. E. Maraskovsky, E. Daro, E. Roux, M. Teepe, C.R. Maliszewski, J. Hoek, D. Caron, M.E. Lebsack, and H.J. McKenna, In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood, 96: 878-884, 2000.
55. P.R. Streeter, N.I. Minster, L.E. Kahn, W.F. Hood, L.E. Vickery, T.L. Thurman, J.B. Monahan, J.K. Welply, J.P. McKearn, and S.L. Woulfe, Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor. Exp. Hematol., 29: 41-50, 2001.
56. A.M. Farese, C.J. Redinger, D.B. Casey, L.E. Kahn, C. Fox, and T.J. MacVittie, Progenipoietin-induced dendritic cell mobilization and collection via apheresis in normal rhesus macaques (abst 132). Proc. Am. Assoc. Cancer Res., 96: 24, 2001.
57. G.Y. Ishioka, J. Fikes, M. Qin, C. Gianfrani, R.W. Chesnut, L.E. Kahn, P.R. Streeter, S.L. Woulfe, and A. Sette, Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. Vaccine., 19: 3710-3719, 2001.
58. P. Bjorck, W.-R. Lie, S.L. Woulfe, B.K. Klein, W. Olson, and W.J. Storkus, Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model (abst 1266). Blood, 96: 294a, 2000.
59. M. Arpinati, C.L. Green, S. Heimfeld, J.E. Heuser, and C. Anasetti, Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood., 95: 2484-2490, 2000.
60. S. Vuckovic, M. Kim, D. Khalil, A.-M. McGee, N.R. Williams, L. Brown, C. Kelly, R.L. Rodwell, S. Wright, K.M. Taylor, G.R. Hill, and D.N.J. Hart, Dendritic cell analysis in G-CSF mobilized normals and patients (abst 1630). Blood, 96: 378a, 2000.
61. S. Ferrari, B. Rovati, C. Porta, A. Riccardi, and M. Danova, High dose cyclophosphamide plus G-CSF causes an impaired mobilization of dendritic cells into the peripheral blood of breast cancer patients (abst 120). Proc. Am. Assoc. Cancer Res., 96: 22, 2001.
62. B. Pulendran, J. Banchereau, S. Burkeholder, E. Kraus, E. Guinet, C. Chalouni, D. Caron, C. Maliszewski, J. Davoust, J. Fay, and K. Palucka, Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol., 165: 566-572, 2000.
63. S. Lonial, H. Rosenthal, B. Feinstein, J. Cherry, M. Dunzel, and E.K. Waller, A randomized study of G-CSF vs. the combination of G-CSF/GM-CSF on mobilization of dendritic cells in peripheral stem cell grafts (abst 2229). Blood, 96: 518a, 2000.
64. P. Lissoni, A. Bonfanti, V. Bordin, S. Barni, L. Vigore, R. Ferrante, F. Rovelli, and L. Fumagalli, Malignancy: Changes in circulating immature and mature dendritic cells during IL-2 cancer immunotherapy and their relation with lymphocyte increase and clinical response. Hematol., 5: 117-125, 2000.
65. M. Merad, T. Sugie, E. Engleman, and L. Fong, Dendritic cells can be directly manipulated in vivo to mediate effective antitumor immunity. (abst 980). Proc. Am. Assoc. Cancer Res., 42: 182, 2001.
66. L. Borges, R.E. Miller, J. Jones, K. Ariail, J. Whitmore, W. Fanslow, and D.H. Lynch, Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol., 163: 1289-1297, 1999.
67. S. Morel, F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.C. Cerottini, T. Boon, J.E. Gairin, and B.J. Van den Eynde, Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity., 12: 107-117, 2000.
68. H.T. Maecker, S. Auffermann-Gretzinger, L.E. Nomura, A. Liso, D.K. Czerwinski, and R. Levy, Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res., 7(3 Suppl): 902s-908s, 2001.
69. Y. Li, M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L.W. Kwak, and H.K. Lyerly, Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood, 96: 2828-2833, 2000.
70. L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G.A. Fisher, M.M. Davis, and E.G. Engleman, Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA., 98: 8809-8814, 2001.
71. T.N. Bullock, T.A. Colella, and V.H. Engelhard, The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol., 164: 2354-2361, 2000.
72. D. Boczkowski, S.K. Nair, D. Snyder, and E. Gilboa, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
73. D.A. Mitchell, and S.K. Nair, RNA transfected dendritic cells as cancer vaccines. Curr. Opin. Mol. Ther. 2: 176-181, 2000.
74. V.F. Van Tendeloo, P. Ponsaerts, F. Lardon, G. Nijs, M. Lenjou, C. Van Broeckhoven, D.R. Van Bockstaele, and Z.N. Berneman, Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood, 98: 49-56, 2001.
75. I. Strobel, S. Berchtold, A. Gotze, U. Schulze, G. Schuler, and A. Steinkasserer, Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther., 7: 2028-2035, 2000.
76. S.K. Nair, D. Boczkowski, M. Morse, R.I. Cumming, H.K. Lyerly, and E. Gilboa, Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol., 16: 364-369, 1998.
77. A. Heiser, M.A. Maurice, D.R. Yancey, N.Z. Wu, P. Dahm, S.K. Pruitt, D. Boczkowski, S.K. Nair, M.S. Ballo, E. Gilboa, and J. Vieweg, Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol., 166: 2953-2960, 2001.
78. D. Boczkowski, S.K. Nair, J.H. Nam, H.K. Lyerly, and E. Gilboa, Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res., 60: 1028-1034, 2000.
79. J. Bubenik, Genetically engineered dendritic cell-based cancer vaccines. Int. J. Oncol., 18: 475-478, 2001.
80. K.M. Ardeshna, A.R. Pizzey, N.S. Thomas, S. Orr, D.C. Linch, and S. Devereux, Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol., 108: 817-824, 2000.
81. N. Chinnasamy, D. Chinnasamy, J.F. Toso, R. Lapointe, F. Candotti, R.A. Morgan, and P. Hwu, Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum. Gene Ther., 11: 1901-1099, 2000.
82. J. Dyall, J.B. Latouche, S. Schnell, and M. Sadelain, Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood, 97: 114-121, 2001.
83. + cell-derived dendritic cells by adenoviral/polycation complex. Br. J. Haematol., 111: 344-350, 2000.
84. D. Rea, M.J. Havenga, M. van Den Assem, R.P. Sutmuller, A. Lemckert, R.C. Hoeben, A. Bout, C.J. Melief, and R. Offringa, Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol., 166: 5236-5244, 2001.
85. M. Brown, Y. Zhang, S. Dermine, E.A. de Wynter, C. Hart, H. Kitchener, P.L. Stern, M.A. Skinner, and S.N. Stacey, Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther., 7: 1680-1689, 2000.
86. C.J. Kim, J. Cormier, M. Roden, L. Gritz, G.P. Mazzara, P. Fetsch, Y. Hijazi, K.H. Lee, S.A. Rosenberg, and F.M. Marincola, Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann. Surg. Oncol., 5: 64-76, 1998.
87. M. Zhu, H. Terasawa, J. Gulley, D. Panicali, P. Arlen, J. Schlom, and K.Y. Tsang, Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res., 61: 3725-3734, 2001.
88. Z. Chen, T. Moyana, A. Saxena, R. Warrington, Z. Jia, and J. Xiang, Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer., 93: 539-548, 2001.
89. M. Shaif-Muthana, C. McIntyre, K. Sisley, I. Rennie, and A. Murray, Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res., 60: 6441-6447, 2000.
90. G. Ferlazzo, C. Semino, G.M. Spaggiari, M. Meta, M.C. Mingari, and G. Melioli, Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int. Immunol., 12: 1741-1747, 2000.
91. L.A. Lambert, G.R. Gibson, M. Maloney, and R.J. Barth Jr., Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J. Immunother., 24: 232-236, 2001.
92. T. Kurokawa, M. Oelke, and A. Mackensen, Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int. J. Cancer., 91: 749-756, 2001.
93. Y. Zeng, H. Feng, L. Whitesell, and E. Katsanis, Dendritic cells mature in response to heat stressed apoptotic tumor cells and induce specific immunity in vitro (abst 978). Proc. Am. Assoc. Cancer Res., 42: 182, 2001.
94. E. Nikitina, and D.I. Gabrilovich, Dendritic cell administration in combination with apoptosis inducing therapy: A proof of concept (Abst 979). Proc. Am. Assoc. Cancer Res., 42: 182, 2001.
95. J.C. McLaughlin, and J.J. Mule, A new strategy of cancer immunotherapy that involves dendritic cells and apoptosis inducing agents. (abst 977). Proc. Am. Assoc. Cancer Res., 42: 182, 2001.
96. J. Gong, D. Chen, M. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Ou, G.J. Rowse, S.J. Gendler, and D. Kufe, Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA., 95: 6279-6283, 1998.
97. J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe, Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol., 165: 1705-1711, 2000.
98. S. Koido, Y. Tanaka, D. Chen, D. Kufe, and J. Gong, Induction of specific antitumor immunity by CTL generated from HLA matched and unmatched dendritic/tumor fusion cells (abst 128). Proc. Am. Assoc. Cancer Res., 42: 24, 2001.
99. M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler, Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res., 61: 6445-6450, 2001.
100. M. Toungouz, M. Libin, F. Bulte, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman, and T. Velu, Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukoc. Biol., 69: 937-943, 2001.
101. R. Lau, J. Kuniyoshi, G. Jeffery, V. Marty, J. Snively, S. Groshen, and J. Weber, Phase II trial of CD40 ligand treated peptide pulsed dendritic cells plus IL-2 in advanced melanoma (abst 1054). Proc. Am. Soc. Clin. Oncol., 20: 264a, 2001.
102. + T cells (abst 117). Proc. Am. Assoc. Cancer Res., 42: 22, 2001.
103. M.V. Dhodapkar, R.M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj, Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med., 193: 233-238, 2001.
104. M.V. Dhodapkar, R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, and N. Bhardwaj, Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest., 104: 173-180, 1999.
105. M.A. Morse, R.E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H.K. Lyerly, Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59: 56-58, 1999.
106. + hematopoietic progenitor cells. Cancer Immunol. Immunother., 48: 118-122, 1999.
107. L.A. Lambert, G.R. Gibson, M. Maloney, B. Durell, R.J. Noelle, and R.J. Barth, Jr., Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res., 61: 641-646, 2001.
108. L. Fong, D. Brockstedt, C. Benike, L. Wu, and E.G. Engleman, Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol., 166: 4254-4259, 2001.
109. K.A. Candido, K. Shimizu, J.C. McLaughlin, R. Kunkel, J.A. Fuller, B.G. Redman, E.K. Thomas, B.J. Nickoloff, and J.J. Mule, Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents. Cancer Res., 61: 228-236, 2001.
110. Y. Tong, I.D. Goldberg, and R.G. Pergolizzi, Induction of systemic and therapeutic antitumor immunity using local irradiation and intratumoral administration of immature dendritic cells (abst 990). Proc. Am. Assoc. Cancer Res., 42: 184, 2001.
111. P.L. Triozzi, R. Khurram, W.A. Aldrich, M.J. Walker, J.A. Kim, and S. Jaynes, Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer., 89: 2646-2654, 2000.
112. A. Ribas, L.H. Butterfield, B. Hu, V.B. Dissette, W.S. Meng, A. Koh, K.J. Andrews, M. Lee, S.N. Amar, J.A. Glaspy, W.H. McBride, and J.S. Economou, Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res., 60: 2218-2224, 2000.
113. R. Hajek, and A.W. Butch, Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med. Oncol., 17: 2-15, 2000.
114. A. Liso, K.E. Stockerl-Goldstein, S. Auffermann-Gretzinger, C.J. Benike, V. Reichardt, A. van Beckhoven, R. Rajapaksa, E.G. Engleman, K.G. Blume, and R. Levy, Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant, 6: 621-627, 2000.
115. V.L. Reichardt, S. Wirths, C. Milazzo, P. Brossart, G. Stuhler, H. Einsele, W. Brugger, and L. Kanz, Specific immunotherapy of multiple myeloma patients using idiotype pulsed serum free generated dendritic cells (abst 701). Blood, 96: 16a, 2000.
116. M. MacKenzie, M.V. Peshwa, T. Wun, J. Wolf, J. Mason, V. Caggiano, C. Redfern, G. Strang, and F. Valone, Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge) (abst 713). Blood., 96: 166a, 2000.
117. J. Banchereau, A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman, and J. Fay, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 61: 6451-6458, 2001.
118. M.C. Panelli, J. Wunderlich, J. Jeffries, E. Wang, A. Mixon, S.A. Rosenberg, and F.M. Marincola, Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother., 23: 487-498, 2000.
119. A. Ribas, L.H. Butterfield, H.T. Vu, S. Amarnani, V.B. Dissette, D.K. Oseguera, W.H. McBride, J.A. Glaspy, and J.S. Economou, Dose and route of dendritic cell-based vaccination for further human testing: A phase I trial (abst 1069). Proc. Am. Soc. Clin. Oncol., 20: 268a, 2001.
120. J.W. Vieweg, D. Coleman, M. Maurice, D. Yancey, P. Dahm, M. Naoe, E. Gilboa, and A. Heiser. Immunotherapy of prostate cancer using dendritic cells transfected with PSA RNA: Results of a phase I trial (abst 1003). Proc. Am. Soc. Clin. Oncol., 20: 251a, 2001.
121. B.A. Tjoa, R.R. Bader, A.L. Boynton, M.L. Bosch, and M.L. Salgaller, Preclinical target validation demonstrating the immunity of a dendritic cell-based vaccine for patients with advanced brain cancer (abst 139). Proc. Am. Assoc. Cancer Res., 42: 26, 2001.
122. J.S. Yu, C.J. Wheeler, P.M. Zeltzer, H. Ying, P.K. Lee, F. Incardona, W.H. Yong, R.C. Thompson, M.S. Riedinger, and K.L. Black, Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma (abst 1478). Proc. Am. Assoc. Cancer Res., 42: 274, 2001.
123. J.S. Yu, C.J. Wheeler, P.M. Zeltzer, H. Ying, D.N. Finger, P.K. Lee, W.H. Yong, F. Incardona, R.C. Thompson, M.S. Riedinger, W. Zhang, R.M. Prins, and K.L. Black, Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res., 61: 842-847, 2001.
124. P. Brossart, S. Wirths, G. Stuhler, V.L. Reichardt, L. Kanz, and W. Brugger, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96: 3102-3108, 2000.